CA2900529A1 - Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma - Google Patents

Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma Download PDF

Info

Publication number
CA2900529A1
CA2900529A1 CA2900529A CA2900529A CA2900529A1 CA 2900529 A1 CA2900529 A1 CA 2900529A1 CA 2900529 A CA2900529 A CA 2900529A CA 2900529 A CA2900529 A CA 2900529A CA 2900529 A1 CA2900529 A1 CA 2900529A1
Authority
CA
Canada
Prior art keywords
fragment
biological sample
subject
bcma
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2900529A
Other languages
English (en)
French (fr)
Inventor
James R. Berenson
Haiming Chen
Eric Sanchez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST MYELOMA & BONE CANCER RES
Original Assignee
INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH filed Critical INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH
Publication of CA2900529A1 publication Critical patent/CA2900529A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/57505—
    • G01N33/57557—
    • G01N33/57585—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CA2900529A 2013-02-08 2014-02-07 Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma Abandoned CA2900529A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762753P 2013-02-08 2013-02-08
US61/762,753 2013-02-08
PCT/US2014/015338 WO2014124280A1 (en) 2013-02-08 2014-02-07 Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma

Publications (1)

Publication Number Publication Date
CA2900529A1 true CA2900529A1 (en) 2014-08-14

Family

ID=51300158

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2900529A Abandoned CA2900529A1 (en) 2013-02-08 2014-02-07 Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma

Country Status (5)

Country Link
US (2) US10126301B2 (enExample)
EP (1) EP2954330A4 (enExample)
JP (2) JP2016507066A (enExample)
CA (1) CA2900529A1 (enExample)
WO (1) WO2014124280A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
AU2016347516A1 (en) 2015-10-30 2018-05-10 Glaxosmithkline Intellectual Property Development Limited Prognostic method
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
EP3458853B1 (en) 2016-05-16 2022-09-07 Onco Tracker, Inc. Improved methods for monitoring immune status of a subject
CA3052779A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018160553A1 (en) * 2017-02-28 2018-09-07 Menarini Silicon Biosystems, Inc. Improved kits and assays to detect circulating multiple myeloma cells from blood
EP3639028B1 (en) 2017-06-13 2025-10-15 Onco Tracker, Inc. Diagnostic, prognostic, and monitoring methods for breast cancer
ES2644580B2 (es) * 2017-07-26 2018-06-04 Universitat Politècnica De València Procedimiento de diagnóstico de lupus eritematoso sistémico (les)
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CN111886012A (zh) 2017-11-06 2020-11-03 朱诺治疗学股份有限公司 细胞疗法与γ分泌酶抑制剂的组合
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
ES2983797T3 (es) * 2018-08-31 2024-10-24 Hoffmann La Roche Timidina cinasa (TK-1) en índices pronóstico para LDLBG
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CN120775051A (zh) 2019-05-21 2025-10-14 诺华股份有限公司 Cd19结合分子及其用途
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
GB2623199A (en) 2021-04-08 2024-04-10 Marengo Therapeutics Inc Multifunctional molecules binding to TCR and uses thereof
CN117305458B (zh) * 2023-10-20 2024-06-21 四川省医学科学院·四川省人民医院 TKTmRNA检测试剂在制备多发性骨髓瘤筛查试剂盒中的用途及试剂盒

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
CA2260014A1 (en) 1996-07-10 1998-01-15 Meiji Milk Products Co., Ltd. Novel use of mk family as hematopoietic factor
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2002306596B2 (en) 2001-02-27 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
WO2003022877A1 (en) 2001-09-06 2003-03-20 Biogen Idec Ma Inc. Crystal structure of baff, and use thereof in drug design
AU2004220078A1 (en) 2003-03-07 2004-09-23 Xencor, Inc BAFF mutants with at least one amino acid substitution and methods of their production
JP5570681B2 (ja) 2004-08-31 2014-08-13 興和株式会社 抗ヒトｂａｆｆ抗体
CA2583900A1 (en) 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
WO2007039489A1 (en) * 2005-09-26 2007-04-12 Apotech Corporation Antibodies against april as biomarkers for early prognosis of lymphoma patients
WO2007053732A2 (en) * 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
US8202698B2 (en) * 2005-11-08 2012-06-19 Biogen Idec Ma Inc. Methods of evaluating BAFF
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
SI1966202T1 (sl) 2005-12-13 2012-01-31 Incyte Corp S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
US20080058316A1 (en) 2006-02-27 2008-03-06 The Johns Hopkins University Cancer treatment with gama-secretase inhibitors
ES2382777T3 (es) 2006-05-03 2012-06-13 Government Of The United States Of America,As Represented By The Secretary, Department Of Health And Human Services Receptor de células T quimérico y materiales relacionados y métodos de uso
EP4606378A3 (en) 2007-06-13 2025-11-05 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-( 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3- cyclopentylprop anenitrile
AU2009239437B2 (en) 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
HUE029619T4 (en) 2009-03-10 2017-07-28 Biogen Ma Inc Anti-bcma antibodies
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
CA2833820C (en) * 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
CA2889764C (en) 2012-11-01 2023-10-10 Martin Lipp An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
US20160331754A1 (en) 2014-01-20 2016-11-17 Gilead Sciences, Inc. Therapies for treating cancers
KR102526945B1 (ko) 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
EP4233870A3 (en) 2014-05-28 2024-01-24 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
EP3154596A4 (en) 2014-06-10 2018-01-24 Institute for Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
PL3179992T3 (pl) 2014-08-11 2022-08-16 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora BTK, inhibitora PD-1 i/lub inhibitora PD-L1
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
CN113603795A (zh) 2014-12-05 2021-11-05 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
EP3271483B1 (en) 2015-03-17 2021-07-21 Mayo Foundation for Medical Education and Research Methods and materials for assessing and treating cancer
SG10201913841SA (en) 2015-07-24 2020-03-30 Oncotracker Inc Gamma secretase modulators for the treatment of immune system dysfunction
UA127515C2 (uk) 2015-08-17 2023-09-20 Янссен Байотек, Інк. Антитіло до всма, біспецифічна антигензв'язувальна молекула, що зв'язує всма і cd3, і їх використання
AU2016347516A1 (en) 2015-10-30 2018-05-10 Glaxosmithkline Intellectual Property Development Limited Prognostic method
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
EP3458853B1 (en) 2016-05-16 2022-09-07 Onco Tracker, Inc. Improved methods for monitoring immune status of a subject
RU2019105693A (ru) 2016-08-01 2020-09-01 Новартис Аг Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага
WO2018085363A2 (en) 2016-11-02 2018-05-11 Berenson James Richard Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
EP3639028B1 (en) 2017-06-13 2025-10-15 Onco Tracker, Inc. Diagnostic, prognostic, and monitoring methods for breast cancer
JP2020528885A (ja) 2017-07-19 2020-10-01 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
WO2020092792A2 (en) 2018-10-31 2020-05-07 Oncotracker, Inc. Method of enhancing immune-based therapy

Also Published As

Publication number Publication date
JP2016507066A (ja) 2016-03-07
US12174189B2 (en) 2024-12-24
US20160131654A1 (en) 2016-05-12
WO2014124280A1 (en) 2014-08-14
US10126301B2 (en) 2018-11-13
JP2018136344A (ja) 2018-08-30
US20190107541A1 (en) 2019-04-11
EP2954330A1 (en) 2015-12-16
EP2954330A4 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
US12174189B2 (en) Diagnostic, prognostic, and monitoring methods for chronic lymphocytic leukemia
EP3402515B1 (en) Improved methods for monitoring immune status of a subject
AU2014266223B2 (en) Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US20180074074A1 (en) Homogenous and heterogeneous assays and systems for determination of ocular biomarkers
EP3458853B1 (en) Improved methods for monitoring immune status of a subject
EP3639028B1 (en) Diagnostic, prognostic, and monitoring methods for breast cancer
DK2551673T3 (en) Methods for detecting cancer infiltration in the central nervous system
CN106290812A (zh) B细胞恶性肿瘤相关抗原表达量检测试剂盒及检测方法
WO2018085363A2 (en) Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
CA3010019C (en) Improved methods for monitoring immune status of a subject
HK40082699A (en) Improved methods for monitoring immune status of a subject
JP7577647B2 (ja) Ｄｌｂｃｌについての予後指標におけるチミジンキナーゼ（ｔｋ－１）
HK40000182B (en) Improved methods for monitoring immune status of a subject
HK40007456B (en) Improved methods for monitoring immune status of a subject
HK40007456A (en) Improved methods for monitoring immune status of a subject
WO2025195496A1 (en) Immunotherapy for ox40 expressing cancer
JP2020509374A (ja) 早期膵がん検出アッセイ
KR20150037321A (ko) 방사선 피폭에 의한 간 손상 예측용 바이오마커 및 그 예측방법
WO2015151056A2 (en) Mab-fcrn assay

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200207